Fate Therapeutics (FATE) Preferred Stock Liabilities (2012 - 2013)
Fate Therapeutics (FATE) posted Preferred Stock Liabilities of $56.5 million for Q3 2013, little changed on a QoQ basis from $56.5 million in Q4 2012.
Fate Therapeutics (FATE) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends
Fate Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $56.5 million for Q3 2013.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $56.5 million in Q3 2013, while the trailing twelve-month figure through Sep 2013 was $56.5 million (changed N/A YoY) and the FY2012 annual result came in at $56.5 million, up 12.36% from the prior year.
- Preferred Stock Liabilities was $56.5 million for Q3 2013 at Fate Therapeutics, roughly flat from $56.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $56.5 million in Q4 2012 and bottomed at $56.5 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 56.53 Mn |
| Dec 31, 2012 | 56.53 Mn |